News

Levosimendan Fails to Impress in Acute Heart Failure Studies

Publish date: February 15, 2006
PDF Download

 

Dr. Packer is a consultant to Abbott Laboratories and Orion Pharma, which funded REVIVE II and SURVIVE. Dr. Mebazaa is a consultant to Abbott.

Intravenous diuretics will remain the initial intervention for patients who present with ADHF. DR. PACKER

Pages

Recommended Reading

Elevated Fibrinogen Predicts PVD Before Age 60
MDedge Family Medicine
Pharmacy Service Helps PAD Patients Achieve Lipid Control
MDedge Family Medicine
Novel Postmarketing Surveillance System Confirms Bosentan's Safety
MDedge Family Medicine
Post-MI Depression, Anxiety Underappreciated
MDedge Family Medicine
Brief Questionnaire Identifies MI Patients Needing Anxiety Treatment
MDedge Family Medicine
Echocardiography Ferrets Out Post-Myocardial Infarction Risk
MDedge Family Medicine
Amiodarone Plus β-Blocker Prevent Implant Shocks
MDedge Family Medicine
Guidant's Woes Make Patients Leery of ICDs : The device manufacturer has been at the center of controversy about disclosing malfunctions.
MDedge Family Medicine
Automated Home Monitoring Found To Improve Heart Failure Outcomes
MDedge Family Medicine
For Heart Implant Patients, Feelings Of Depression, Anxiety Will Ease
MDedge Family Medicine